$REPL News

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

Replimune Group (REPL) Stock Looks Rich After A 141% Run

Replimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes Clear

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma

Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript

Replimune to Present at the Cantor Global Healthcare Conference 2026

JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’

Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit

Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Transcript